Replies to post #278010 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
Actual Study Start Date : July 9, 2018
Actual Primary Completion Date : September 30, 2020
Actual Study Completion Date : September 30, 2020
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics: Parkinson disease
MedlinePlus related topics: Dementia Parkinson's Disease
U.S. FDA Resources

https://clinicaltrials.gov/ct2/show/NCT03774459

[Blur]

georgejjI,

It mentions sleep disorders like it’s been discussed here for year’s

But let me ask you or other in the know, two questions;

Is this drug administered before sleep?

Does it activate more efficiently while sleeping?

Maybe to be revealed?

Thanks